Grant: Project Grant
Ottawa Hospital Research Institute
$405,451.00
Canadian Extension of the Candesartan Adjunctive Bipolar Depression Trial (CADET)
FY 2024-25
Summary
People with bipolar disorder spend as much as half their lives suffering from depression. Medications for bipolar disorder more often address the manic phase of the illness, and more research is needed into medications for bipolar depression. A drug called candesartan is already used in Canada to treat high blood pressure and heart failure. Research suggests that candesartan may have mood benefits. Candesartan may also be helpful in treating bipolar depression. Because people with bipolar disorder face a greater risk of heart and blood vessel issues, candesartan may also provide an additional benefit by reducing these issues.
Candesartan is already widely available in Canada, inexpensive, and safe for use as directed by a physician for high blood pressure and heart failure. In this study, we will assess its effectiveness and safety among patients with bipolar disorder who are experiencing depression. Patients will be assigned to one of two groups: the experimental group that will receive candesartan and the control group that will receive a placebo. Researchers will meet with patients to carry out standardized psychological interviews that assess their mental health. The team will also collect blood samples from participants at set periods of time to ensure the drug is safe for use.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
523757
Name
Fiedorowicz Jess G
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
Canadian Extension of the Candesartan Adjunctive Bipolar Depression Trial (CADET)
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$405,451
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Adults; Bipolar Disorder; Candesartan; Depressive Symptoms; Randomized Clinical Trial; Renin-Angiotensin System
Abstract
People with bipolar disorder spend as much as half their lives suffering from depression. Medications for bipolar disorder more often address the manic phase of the illness, and more research is needed into medications for bipolar depression. A drug called candesartan is already used in Canada to treat high blood pressure and heart failure. Research suggests that candesartan may have mood benefits. Candesartan may also be helpful in treating bipolar depression. Because people with bipolar disorder face a greater risk of heart and blood vessel issues, candesartan may also provide an additional benefit by reducing these issues.
Candesartan is already widely available in Canada, inexpensive, and safe for use as directed by a physician for high blood pressure and heart failure. In this study, we will assess its effectiveness and safety among patients with bipolar disorder who are experiencing depression. Patients will be assigned to one of two groups: the experimental group that will receive candesartan and the control group that will receive a placebo. Researchers will meet with patients to carry out standardized psychological interviews that assess their mental health. The team will also collect blood samples from participants at set periods of time to ensure the drug is safe for use.
Competitiondate
202503
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Fiedorowicz, Jess G; Solmi, Marco
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $405,451~ $0~